- OUTLOOK
Why big pharma has abandoned antibiotics
Access options
Nature 586, S50-S52 (2020)
doi: https://doi.org/10.1038/d41586-020-02884-3
This article is part of Nature Outlook: Antimicrobial resistance, an editorially independent supplement produced with the financial support of third parties. About this content.
References
Towse, A. et al. Health Policy 121, 1025–1030 (2017).
Kuo, Y.-T. et al. Lancet Gastroenterol. Hepatol. 2, 707–715 (2017).
Roope, L. S. J. et al. Science 364, eaau4679 (2019).
Sharma, P. & Towse, A. New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options (OHE, 2014).
Projan, S. J. et al. Curr. Opin. Microbiol. 6, 427–430 (2003).
Stokes, J. M. et al. Cell 180, 688–702 (2020).
Enne, V. I., Livermore, D. M., Stephens, P. & Hall, L. M. C. Lancet 357, 1325–1328 (2001).
Sundqvist, M. et al. J. Antimicrob. Chemotherpy 65, 350– 360 (2010).
Schneider, M., Harrison, N. R., Daniel, G. W. & McClellan, M. B. Delinking US Antibiotic Payments through a Subscription Model in Medicare (Duke-Margolis Center for Health Policy, 2020).